依达拉奉和低分子肝素联合治疗急性进展型脑梗死的疗效观察

目的探讨依达拉奉和低分子肝素(LMWH)联合治疗急性进展型脑梗死的疗效。方法将64例急性进展型脑梗死患者随机分为联合治疗组和对照组各32例。2组患者在常规治疗的基础上均给予LMWH 5 000 U腹部皮下注射,每12 h 1次,连用10 d。联合治疗组再给予依达拉奉30mg加入生理盐水100ml静脉滴注,每天2次,连用10 d。分别于治疗前和治疗后进行神经功能缺损程度评分(NDS)及凝血功能检查。结果联合治疗组的总有效率(93.7%)明显高于对照组(71.9%)(P<0.05);2组治疗后NDS改善显著(P<0.01),血浆纤维蛋白原含量、凝血功能指标差异无统计学意义(均P>0.05)。联合治疗组出现轻度血转氨酶、尿素氮升高各1例,经相应治疗,均短期内恢复正常。结论依达拉奉联合LMWH治疗急性进展型脑梗死效果显著,有助于改善神经功能,无明显不良反应。

Therapeutic effects of edaravone and low molecular weight heparin on patients with acute progressive cerebral infarction

Objective To investigate the therapeutic effect of edaravone and low molecular weight heparin （LMWH） on acute progressive cerebral infarction. Methods Consecutive 64 patients with acute progressive cerebral infarction were randomly divided into union therapy group （ n = 32 ） and control group （ n = 32 ）. The patients in both two groups underwent conventional treatment, and were administrated low molecular weight heparin 5 000 U subcutaneous injection at abdomen, one time every 12 hours ,lasted for 10 d. In union therapy group ,patients were added with edaravone （30 mg intravenously,twice per day, lasted for 10 d）. The neurological functional dificit score （NDS） and clotting function tests were examined and compared between pre and post treatment. Results The total effective rate in union therapy group （93.7%） was significantly higher than that in the control group （71.9%） （ P 〈0.05）. Neurological function dificit score of two groups after treatment improve significantly （ P 〈 0.01 ）. Plasma fibrinogen contents and coagulation function had no statistically significant difference （ all P 〉 0.05 ） after treatment. In the union therapy group, there were 1 case with liver transaminases mildly elevated,l case with blood urea nitrogen elevated. The complication dismissed after corresponding treatment in short term. Conclusion It demonstrated that combination edaravone with low-molecular weight heparin on treating acute progressive cerebral infarction had better therapeutic effect, and it could improve neurological function and no obvious adverse reactions.